CXCL12/SDF‑1α induces migration via SRC‑mediated CXCR4‑EGFR cross‑talk in gastric cancer cells

Cheng,Yu; Qu,Jinglei; Che,Xiaofang; Xu,Ling; Song,Na; Ma,Yanju; Gong,Jing; Qu,Xiujuan; Liu,Yunpeng

doi:10.3892/ol.2017.6389

CXCL12/SDF‑1α induces migration via SRC‑mediated CXCR4‑EGFR cross‑talk in gastric cancer cells

Authors:
- Yu Cheng
- Jinglei Qu
- Xiaofang Che
- Ling Xu
- Na Song
- Yanju Ma
- Jing Gong
- Xiujuan Qu
- Yunpeng Liu
View Affiliations

Affiliations: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: June 15, 2017 https://doi.org/10.3892/ol.2017.6389
Pages: 2103-2110
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is the primary cause of mortality in patients with advanced gastric carcinoma, and multiple signaling pathways promote the development of this condition. Stromal cell‑derived factor‑1 (SDF‑1α/CXCL12), the main ligand for CXC chemokine receptor‑4 (CXCR4), serves an important role in gastric cancer cell migration. Previous studies have demonstrated that CXCL12 could also stimulate the secretion of epidermal growth factor receptor (EGFR) ligands, including amphiregulin and heparin‑binding epidermal growth factor‑like growth factor, from gastric cancer cells, resulting in an increase in the ability of migration. However, it remains to be elucidated whether CXCL12 activates EGFR intracellular signaling and therefore stimulates migration in gastric cancer. The present study demonstrated that three gastric cancer cell lines, SGC‑7901, MGC‑803 and BGC‑823, all expressed CXCR4. The increased chemotactic migratory ability stimulated by CXCL12 was effectively abrogated by the CXCR4 antagonist, AMD3100. Furthermore, a rapid phosphorylation of Akt/extracellular signal‑regulated kinase (ERK)/EGFR was demonstrated to be involved in CXCL12/CXCR4‑induced gastric cancer cell migration. Knockdown of EGFR gene or the use of a monoclonal antibody against EGFR (C225) blocked the activation of ERK/Akt and partially prevented the ability of migration induced by CXCL12, which indicated that EGFR signaling is located downstream of CXCL12. In addition, it was also revealed that the activation of non‑receptor tyrosine kinase c‑steroid receptor co‑activator (SRC) and the formation of the SRC/EGFR heterodimer are promoted by CXCL12, whereas the SRC inhibitor, PP2, blocks the SRC/EGFR heterodimer and the activation of EGFR, as well as CXCR4‑meditated migration induced by CXCL12. The present results indicated that SRC mediates a potential CXCR4‑EGFR cross‑talk, and thereby utilizes the EGFR‑Akt/ERK axis to promote cellular migration. The present study provided a novel insight into the underlying regulatory mechanisms of the CXCL12/CXCR4 pathway in gastric cancer cell migration.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shah MA: Update on metastatic gastric and esophageal cancers. J Clin Oncol. 33:1760–1769. 2015. View Article : Google Scholar : PubMed/NCBI
3	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zou YR, Kottmann AH, Kuroda M, Taniuchi I and Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393:595–599. 1998. View Article : Google Scholar : PubMed/NCBI
5	Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD and Dubrovska A: Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. Onco Targets Ther. 6:1347–1361. 2013.PubMed/NCBI
6	Ying J, Xu Q, Zhang G, Liu B and Zhu L: The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol. 29:1716–1722. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wang X, Zhang H, He H, Shen Z, Tang Z, Xu J and Sun Y: Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection. Cancer Sci. 105:1447–1456. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ohtsu H, Dempsey PJ and Eguchi S: ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol. 291:C1–10. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L and Ullrich A: GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem. 386:845–855. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kasina S, Scherle PA, Hall CL and Macoska JA: ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell Prolif. 42:799–812. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K and Yano S: The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 17:3619–3630. 2011. View Article : Google Scholar : PubMed/NCBI
12	Natarajan K and Berk BC: Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol. 332:51–77. 2006.PubMed/NCBI
13	Hopkins MM, Liu Z and Meier KE: Positive and negative cross-talk between lysophosphatidic acid receptor 1, free fatty acid receptor 4, and epidermal growth factor receptor in human prostate cancer cells. J Pharmacol Exp Ther. 359:124–133. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fischer OM, Giordano S, Comoglio PM and Ullrich A: Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem. 279:28970–28978. 2004. View Article : Google Scholar : PubMed/NCBI
15	Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD and Cher ML: CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 3:446–457. 2008. View Article : Google Scholar
16	Martin GS: The hunting of the Src. Nat Rev Mol Cell Biol. 2:467–475. 2001. View Article : Google Scholar : PubMed/NCBI
17	Bendinelli P, Maroni P, Matteucci E and Desiderio MA: Comparative role of acetylation along c-SRC/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes. Biochim Biophys Acta. 1813:1767–1776. 2011. View Article : Google Scholar : PubMed/NCBI
18	Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Rocca GJ Della, Lin F, Kawakatsu H, Owada K, Luttrell DK, et al: Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 283:655–661. 1999. View Article : Google Scholar : PubMed/NCBI
19	Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 17:461–469. 2011. View Article : Google Scholar : PubMed/NCBI
20	Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM and Grandis JR: c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 19:380–392. 2013. View Article : Google Scholar : PubMed/NCBI
21	Peiró G, Ortiz-Martínez F, Gallardo A, Pérez-Balaguer A, Sánchez-Payá J, Ponce JJ, Tibau A, López-Vilaro L, Escuin D, Adrover E, et al: SRC, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer. 111:689–695. 2014. View Article : Google Scholar : PubMed/NCBI
22	Boerner JL: Role of SRC family kinases in acquired resistance to EGFR therapies in cancer. Cancer Biol Ther. 8:704–706. 2009. View Article : Google Scholar : PubMed/NCBI
23	Xu L, Qu X, Li H, Li C, Liu J, Zheng H and Liu Y: Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. Oncol Rep. 32:318–324. 2014.PubMed/NCBI
24	Zhao L, Liu S, Che X, Hou K, Ma Y, Li C, Wen T, Fan Y, Hu X, Liu Y and Qu X: Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors. Int J Mol Med. 36:645–652. 2015.PubMed/NCBI
25	DiPersio JF, Uy GL, Yasothan U and Kirkpatrick P: Plerixafor. Nat Rev Drug Discov. 8:105–106. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H and Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:635–638. 1996. View Article : Google Scholar : PubMed/NCBI
27	Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W and Ratajczak J: The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 20:1915–1924. 2006. View Article : Google Scholar : PubMed/NCBI
28	Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res. 75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
29	Bhola NE and Grandis JR: Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer. Front Biosci. 13:1857–1865. 2008. View Article : Google Scholar : PubMed/NCBI
30	Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T and Schettini G: Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res. 308:241–253. 2005. View Article : Google Scholar : PubMed/NCBI
31	Bromann PA, Korkaya H and Courtneidge SA: The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 23:7957–7968. 2004. View Article : Google Scholar : PubMed/NCBI
32	Parsons JT and Parsons SJ: Src family protein tyrosine kinases: Cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol. 9:187–192. 1997. View Article : Google Scholar : PubMed/NCBI
33	Dittmann K, Mayer C, Kehlbach R, Rothmund MC and Rodemann H Peter: Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol. 92:379–382. 2009. View Article : Google Scholar : PubMed/NCBI
34	Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y and Qu X: Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci. 15:5838–5851. 2014. View Article : Google Scholar : PubMed/NCBI
35	de Nigris F, Schiano C, Infante T and Napoli C: CXCR4 inhibitors: Tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 7:251–264. 2012. View Article : Google Scholar : PubMed/NCBI
36	Mayer EL and Krop IE: Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 16:3526–3532. 2010. View Article : Google Scholar : PubMed/NCBI
37	Montero JC, Seoane S, Ocaña A and Pandiella A: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res. 17:5546–5552. 2011. View Article : Google Scholar : PubMed/NCBI